Cancer Immune Recognition Problem

Cancer immune recognition problem is [[LiuCheng|刘诚]]’s treatment-philosophy frame in E235｜20年内CAR-T治愈癌症？与刘诚博士聊聊癌症治疗的底层哲学. Cancer cells come from the body’s own cells, so the immune system does not automatically treat them like foreign viruses or bacteria. A therapy must therefore distinguish cancer cells from normal cells strongly enough to attack the cancer without creating unacceptable self-damage.

The episode uses this frame to compare treatment types. Chemotherapy exploits fast cell division but harms other fast-dividing cells; targeted drugs and ADCs try to find molecular differences; surgery and radiotherapy remove or damage tumor concentrations locally; [[CARTCellTherapy|CAR-T]] tries to teach immune cells who to attack. This also connects to Cancer Vaccine Platform, where a vaccine strategy similarly treats cancer as an immune-visibility problem.

Key Claims

• Cancer is difficult partly because malignant cells are self cells, not clearly foreign invaders.
• Effective oncology treatment depends on a discrimination problem: find something cancer cells have, express, or do that normal cells do not share at dangerous levels.
• Immune activation is double-edged because too little response permits cancer growth while too much response can damage normal tissue.
• CAR-T Cell Therapy and Cancer Vaccine Platform are adjacent but different answers to the same recognition problem.

Connections

• CAR-T Cell Therapy, In Vivo CAR-T, and Ex Vivo CAR-T Manufacturing - cell-therapy routes that engineer immune recognition.
• Cancer Vaccine Platform and KRAS Oncology Target - vaccine and target-selection branch already present in the wiki.
• Tumor Microenvironment and Solid Tumor CAR-T Constraints - contexts where recognition alone may not be enough.
• Cytokine Release Syndrome - safety consequence when immune activation becomes excessive.